Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zolinza (Vorinostat),VZ501,2021,USA,MDV,350,68,45,55,27.5,32,85,12,15,30,40,15,55,25,15,5,20,35,45,18,7,4,9,6,22,38,42,CHOP,ICE,ABVD,EPOCH,10,8,7,25,55,40,20,50,30,60,2
Zolinza (Vorinostat),VZ502,2022,Canada,Claim Database,420,72,48,52,28.1,35,82,15,12,28,42,18,52,28,14,6,18,33,49,20,8,5,10,7,25,40,45,EPOCH,Hyper-CVAD,ABVD,BEACOPP,12,9,8,28,58,42,18,52,30,65,3
Zolinza (Vorinostat),VZ503,2023,UK,MDV,280,65,52,48,26.8,30,88,10,18,32,38,12,58,22,16,4,22,37,41,16,6,3,8,5,20,35,40,ICE,DHAP,BEACOPP,ABVD,9,7,6,23,53,38,22,48,30,55,2.5
